Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03624517 · ClinicalTrials.gov registry record · Phase 4
Comparison of 24-hours Versus 72-hours of Octreotide Infusion in Preventing Early Rebleed From Esophageal Varices
A Phase 4 study, sponsored by Medical University of South Carolina.
- Terminated
- Registry status
- Phase 4
- Development phase
- 34
- Enrollment target
NCT03624517 is a Phase 4 study that was terminated before completion, run by Medical University of South Carolina. The registered enrollment target is 34 participants.
The verdict
NCT03624517, a Phase 4 study, was terminated before completion, sponsored by Medical University of South Carolina.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 34 participants
- Enrollment target
Study Summary
This study evaluates the safety and efficacy of 24-hour vs 72-hour octreotide infusion after variceal banding in cirrhotic patients with bleeding esophageal varices.
Interventions
- DRUG Octreotide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2018-09-19 |
| Est. Completion | 2024-12-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03624517
The ClinicalTrials.gov registry entry for NCT03624517 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical University of South Carolina, which has 755 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Octreotide is the first listed.
NCT03624517 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03624517 about?
NCT03624517 is a clinical study titled "Comparison of 24-hours Versus 72-hours of Octreotide Infusion in Preventing Early Rebleed From Esophageal Varices". This study evaluates the safety and efficacy of 24-hour vs 72-hour octreotide infusion after variceal banding in cirrhotic patients with bleeding esophageal varices.
What is the current status of trial NCT03624517?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 34 participants. The study started on 2018-09-19. Estimated completion is 2024-12-01.
What interventions are being tested in trial NCT03624517?
The interventions under investigation include: Octreotide (DRUG).
Who is sponsoring clinical trial NCT03624517?
This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.